Key facts
- Osivax’s last known valuation is $12.2M (Jul 2018).
- It has raised $45.4M; the latest was Grant ($19.5M) in Aug 2025.
- Notable investors include Bpifrance, European Innovation Council, European Commission, La French Tech, Gates Foundation — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Osivax
- ·The full record, as it builds
Funding rounds
No funding rounds for Osivax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Osivax
Developer of universal vaccines designed to prevent globally impactful infectious diseases, starting with influenza. The company leverages its technology and acts as a universal vaccine against all existing and emerging coronavirus infections to prevent globally impactful contagious diseases, enabling medical practitioners to treat patients with cancer, influenza, malaria, and other infectious diseases effectively.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2017
- Employees
- 50
- Website
- osivax.com/
- Ownership
- Privately Held (backing)
Osivax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Osivax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Osivax in its N-PORT filings yet. We sweep new filings monthly.